The COOH termini of heterotrimeric guanine nucleotide-binding protein (G protein) α subunits (Gα) are critical for both binding to their cognate G protein-coupled receptors (GPCRs) and determining specificity. Additionally, synthetic peptides corresponding to the COOH-terminus can serve as competitive inhibitors of receptor-G protein interactions, presumably by blocking the site on the GPCR that normally binds the G protein. To selectively antagonize G protein signal transduction events, we have generated minigene vectors that encode 14 unique COOHterminal sequence for the 16 Gα subunits. Minigene vectors expressing Gα COOH-terminal peptides, or the control minigene vector, which expresses the inhibitory Gα subunit (G i ) peptide in random order, can be systematically introduced into cells by transfection and used to determine which G protein underlies a given GPCR-mediated response. Because Gα COOH-terminal minigene vectors selectively block signal transduction through a given G protein, they are a powerful tool for dissecting out which G protein mediates a given biochemical or physiological function. This also provides a novel strategy for exploring the coupling mechanisms of receptors that interact with multiple G proteins, as well as for teasing out the downstream responses mediated by a specific G protein.
Introduction
Many biologically active molecules convey their signals through receptors coupled to heterotrimeric guanine nucleotide binding proteins (G proteins). Molecular cloning has resulted in the identification of 16 distinct G protein α subunits (Gα). Their 14 unique COOH-terminal sequences are commonly divided into four families based on their sequence similarity [see review (1) ; Table 1 ]. The G i family includes G t and G gust (which share a COOH terminus motif), G i1 and G i2 [which also share a COOH terminal motif (G i1/2 )], and G i3 , G o1 , G o2 , and G z ; the G s family members are G s and G olf ; the G q family includes G q , G 11 , G 14 , and G 15/16 (G 15 is the name of the mouse protein; G 16 is the name of the human protein); and the G 12 /G 13 family members are G 12 and G 13 . Similarly, five G protein β (Gβ) and twelve G protein γ (Gγ) subunits have been identified (1) .
Upon activation, G protein-coupled receptors (GPCRs) interact with their cognate G protein, inducing guanosine diphosphate (GDP) release with subsequent guanosine triphosphate (GTP) binding to the α subunit [see review (2, 3) ]. The exchange of GDP for GTP leads to dissociation of Gβγ from Gα, and both subunits go on to initiate unique intracellular signaling responses. For both G proteins and small guanosine triphosphatases (GTPases), the GTP is bound as a complex with Mg 2+ , and the GTP-and Mg 2+ -binding sites are tightly coupled. Dominantnegative constructs of the Gα subunit have been made in which mutations are introduced at residues known to contact the magnesium ion (6) (7) (8) (9) (10) ; these include mutations of the Gly residue within the invariant sequence (G203T; G204A), and mutations of a Ser residue in the effector loop, also known as the switch I region [S47C; (2) ]. Although this approach was successfully used to make dominant-negative GTPases, such as p21 ras (4, 5) , it has been less effective for making dominant-negative G proteins (6) (7) (8) (9) (10) . This problem is probably due to the degree to which Mg 2+ is necessary to support GDP binding. The GTPase p21 ras forms a tight and nearly irreversible GDP•Mg 2+ complex, whereas Gα subunits bind Mg 2+ in the GDP•Mg 2+ complex with lower affinity than in the GTP•Mg 2+ complex (11) (12) (13) .
Thus, we looked to other regions on G protein α subunits that could serve to block activation of G proteins by receptors. Studies using adenosine diphosphate (ADP) ribosylation by pertussis toxin, peptide competition, site-directed mutagenesis, peptide-specific antibodies, and chimeric proteins indicate that the COOH-terminus of Gα is essential for receptor contact. Microinjection studies of intact cells indicate that Gα COOHterminal peptides can competitively block G protein-coupled downstream events [see reviews (2, 14, 15] . The COOHtermini from various G protein α subunits are important sites of receptor binding, and peptides corresponding to the COOHtermini can be used as competitive inhibitors of receptor-G protein interactions (16) (17) (18) . Using a combinatorial peptide library, Martin et al. (19) have shown that specific residues within the COOH-terminus of G t are critical for high-affinity binding of the Gα peptide to rhodopsin. The G protein-receptor interaction is quite specific, because a change of one amino acid can annul the ability of the G i1/2 peptide to bind the A1 adenosine receptor-G protein interface (20) , and changing two amino acids from the G q peptide decreases its ability to block signaling from the thrombin receptor (21) .
To selectively antagonize G protein signal transduction events in vivo by expressing peptides that block the receptor-G protein interface, we generated "minigene" plasmid constructs (Fig. 1 ) that encode COOH-terminal peptide sequences for each of the 14 unique Gα subunits ( Table 1) . As a control, we constructed a minigene vector for the COOH-terminus of G i1/2 in random order (G i R). The minigene plasmid vectors were designed to express the COOH-terminal peptide sequences of the various Gα subunits after their transfection into mammalian cells (21) (22) (23) (24) . This protocol describes details of designing and subcloning the minigenes; the production of Maloney leukemia virus for transduction of the cells; testing for transduction and detection of minigene production; and determining the effect of the minigene of GPCR function. The methods described here have been used successfully to show that both the minigene vectors and the retroviral minigene vectors can specifically block agonist-mediated GPCR responses in a variety of cell types. These vectors serve as important research tools for deciphering which G protein a given receptor uses to transduce its signal. The minigene vector constructs. All Gα COOH-terminal peptide minigenes contain a BamHI restriction enzyme site at the 5′ end, followed by a ribosomal binding site sequence, a Met for translation initiation, a Gly for stabilization of the peptide, the peptide sequence, a stop codon, and a HindIII restriction enzyme site at the 3′ end. The G i R contains the G i1/2 COOH peptide sequence in random order. After annealing, complementary oligonucleotides were ligated into a BamHI-and HindIII-cut pcDNA3.1(-) plasmid vector. pCMV, cytomegalovirus promoter; BGH pA, bovine growth hormone polyadenylation sequence; f1 ori, f1 origin of replication; SV40 ori, simian virus 40 origin of replication; SV40 pA, SV40 polyadenylation sequence; Neo, neomycin resistance gene; RBS, ribosome-binding consensus sequence; Amp, ampicillin resistance gene. 
Materials

Chemicals and Kits
Recipe 3: 1% Serum MCDB 131
Add 1% fetal bovine serum to Serum-Free MCDB 131 (Recipe 2) and sterilize with a 0.2-µm filter. Store at 4°C.
Recipe 4: Complete MCDB 131
Add 5% fetal bovine serum to Serum-Free MCDB 131 (Recipe 2) and sterilize with a 0.2-µm filter. Store at 4°C.
Recipe 5: Complete GP-293 Medium
Fetal bovine serum 50 ml L-glutamine, 200 mM 10 ml
Penicillin-streptomycin 50× solution 10 ml MEM Sodium pyruvate, 100 mM 5 ml
Prepare in 500 ml of DMEM and sterilize with a 0.2-µm filter. Store at 4°C.
Recipe 6: PBS
Dilute in H 2 0 from 10× PBS (VWR). For sterile use, autoclave. Store at 4°C.
Recipe 7: 1°Culture Media
50 parts of Eagle's basal medium with Hank's base (25%) L-glutamine (1 ml of 200 mM L-glutamine to 200 ml of medium), 25 parts of horse serum, and one part of 50% glucose.
Recipe 8: Detachment Buffer
Prepare a 0.05% trypsin solution in 0.5 mM EDTA. Sterilize with a 0.2-µm filter. Store at 4°C. 
Recipe 9: Fractionation Buffer
Instructions Design and Preparation of the Oligonucleotides
The following instructions provide the specific details for the preparation of Gα constructs. The oligonucleotides can be either prepared in the laboratory or ordered from an oligonucleotide synthesis company. The oligonucleotides encoding the last 11 amino acids of the Gα subunits are synthesized with newly engineered 5′ and 3′ ends ( Fig. 1 ). The 5′ end should contain a BamHI restriction enzyme site followed by the human ribosome-binding consensus sequence (5′-GCCGCCACC-3′), a methionine (ATG) for translation initiation, and a glycine (GGA) to protect the ribosome binding site during translation and the nascent peptide against proteolytic degradation. A HindIII restriction enzyme site is synthesized at the 3′ end immediately following the translational stop codon (TGA). The resulting oligonucleotides are 57 bp.
1. Resuspend the oligonucleotides in sterile ddH 2 O to a final concentration of 100 µM.
Anneal the complementary DNAs in 1×
NEBuffer 3 at 85°C for 10 min.
3. Cool slowly to room temperature.
4. Electrophorese the annealed DNAs on a 4% agarose gel with ethidium bromide to visualize.
5. Excise the 57-bp band.
6. Purify the DNA with a Qiagen QIAEX II gel extraction kit according to the manufacturer's instructions.
Construction of Gα COOH-Terminal Minigenes
1. Digest the pcDNA3.1(-) or pRevTRE2 vector with HindIII and BamHI restriction enzymes.
2. Electrophorese the digested vector on a 0.8% agarose gel.
3. Excise the digested vector [5.4 kb for pcDNA3.1(-) or 6.5 kb for pRevTRE2].
4. Purify the vector DNA with a Qiagen QIAEX II gel extraction kit according to the manufacturer's instructions.
5. Ligate the purified vector and the purified oligonucleotides for 1 hour at room temperature with ~400 U of T4 DNA ligase and the provided ligation buffer. 
Cell Culture and Transfection
The following subsections describe two alternative approaches for expression of minigenes. In the first pair, standard cell transfection protocols are provided that use two choices of mammalian cell lines. In the second set, a system is described that involves production of a retroviral vector-minigene construct and infection of cells with this construct.
Human embryonic kidney (HEK) 293 cells
The HEK cells we used stably express the muscarinic acetylcholine receptor (M 2 AChR) at a concentration of ~400 fmol receptor per mg protein (25) . These cells are available from Moritz Bünemann (Institut für Pharmakologie und Toxikologie, Universität Würzburg, 97078 Würzburg, Germany) or can be produced in the laboratory by stably transfecting the M 2 receptor plasmid into the cells. The cells are grown in complete DMEM (Recipe 1) in an atmosphere of 90% air and 10% CO 2 at 37°C. These cells are then analyzed for the ability of the minigene constructs to inhibit M 2 AChR-mediated activation of inwardly rectifying K + (I KACh ) currents using whole cell patch clamp techniques. Because the I KACh channel is formed as a heterotetramer of G protein-regulated inward rectifying K + channels (GIRK), with two GIRK1 and two GIRK4 subunits.
1. Transfect the cells using a standard calcium phosphate procedure (26) with 1 µg of pC1-GIRK1 (rat), 1 µg of pcDNA1-GIRK4 (rat), and 4 µg of the minigene DNA.
2. Incubate the transfected cells in complete DMEM medium (Recipe 1) for 48 hours in an atmosphere of 90% air and 10% CO 2 at 37°C to allow expression of the transfected proteins.
Human microvascular endothelial (HME) cells
Human microvascular endothelial (HME) cells are maintained in Complete MCDB 131 (Recipe 4) in an atmosphere of 95% air and 5% CO 2 at 37°C. Cells are transfected with the minigene plasmids and with a vector containing enhanced green fluorescent protein, pRevTRE2-pEGFP. Transfection efficiency is monitored by visualizing the cells expressing EGFP. These cells are then analyzed for the ability of the minigene constructs to inhibit thrombin-mediated increases in intracellular calcium concentration.
1. Plate cells at 1 × 10 5 cells per ml into 100-mm dishes (10 ml medium) or 6-well plates (2 ml medium) and incubate in an atmosphere of 95% air and 5% CO 2 at 37°C for 2 days or until cells reach 80% confluency.
2. Transiently transfect the cells with minigene vector DNA (2 µg of DNA per 100-mm plate or 500 ng per well in 6-well plates) and 250 ng to 1000 ng of pEGFP DNA using Effectene transfection reagent (Qiagen) according to the manufacturer's instructions. 3. Incubate the cells in complete MCDB 13 medium (Recipe 4) in an atmosphere of 95% air and 5% CO 2 at 37°C for 3 hours.
4. Replace the medium with fresh medium and incubate in an atmosphere of 95% air and 5% CO 2 at 37°C for 48 hours.
5. Re-plate the cells onto coverslips and grow for 48 hours.
6. Analyze using a fluorescent microscope to visualize the EGFP to determine the efficiency of transfection.
Murine Maloney leukemia virus production
The minigene is inserted into the pRevTRE2 vector at its BamHI and HindIII sites. For infection of cultured cells, Murine Maloney leukemia virus production of the minigene is carried out by infecting the pantropic packaging cell line GP-293 with pRevTRE2-minigene and VSV-G, an envelope glycoprotein from the vesicular stomatitis virus, using Effectene reagent.
Enhanced GFP inserted into the parental retroviral vector pRevTRE2-dEGFP can be used as a control for viral infection. The Pantropic Retroviral Expression System allows the pRevTRE2-minigene DNA to be stably introduced into dividing cells. This system produces high-titer virus capable of highly efficient transfer of genes into the broadest possible range of mammalian and nonmammalian cells. 4. Replace the medium with 3 to 5 ml of fresh medium.
5. Collect the medium containing the virus 2 to 3 days posttransfection.
6. Filter the virus-containing medium through a 0.45-µm cellulose acetate filter.
7. Aliquot 500 µl into cryovials and store at −80°C.
Determine the viral titer according to manufacture's instructions.
Note: Virus titer should be at least 1 × 10 5 pfu per ml.
Viral infection of cells
1. Plate GP-293 cells in 6-well plates in Complete GP-293 Medium (Recipe 5).
2. Grow for 12 to 24 hours or until the cells reach 80% density.
3. Infect the cells with 500 µl per well with the pRevTRE2-minigene construct, provided the titer is 1 × 10 6 pfu per ml. Polybrene can be added (final concentration 8 mg/ml).
Note: Polybrene is a polycation that reduces cell surface-associated charges, enhancing the interaction between the retrovirus and the cell membrane. Clontech suggests using a concentration between 2 and 8 µg/ml. However, we found that our cells survived better when Polybrene was not included.
Note: If the titer is low, the volume of virus added can be increased, or the virus stocks can be concentrated by ultracentrifugation. The cells should be infected with a minimum of 1 × 10 5 pfu per ml.
4. Grow the cells with the retroviral construct for 24 h in an atmosphere of 95% air and 5% CO 2 at 37°C.
5. Replace medium with fresh medium containing 2 µg/ml of doxycycline after 24 hours of incubation to induce peptide expression.
6. Incubate for 24 to 48 hours to allow the peptides to be expressed and effective.
Verifying Transfection by RNA Analysis
Transfection of HME cells is evaluated by monitoring expression of EGFP, but to confirm the presence of the minigene constructs in transfected HEK cells, total RNA is isolated, cDNA is made using RT-PCR, and PCR analysis is performed using the cDNA as a template with primers specific for the Gα COOH-terminal sequence. To verify the presence of insert in cells transfected with pcDNA-G i or pcD-NA-G i R constructs, their cDNA is used as a template for PCR with forward and reverse primers that correspond to Gα insert and vector, respectively. The primers for the Gα minigenes amplify a 434-bp fragment only if the insert COOH-terminus oligonucleotides are present; no band is observed in cells transfected with the empty pcDNA3.1(-) vector (24).
Wash the transiently transfected HEK cells twice with 10 ml of PBS (Recipe 6).
Note: This method has been used successfully on both transiently transfected cells and the pRevTRE2 virally infected cells.
2. Lyse the cells with 350 µl of RLT lysis buffer (RNeasy Mini Kit, Qiagen) per 10-cm plate.
3. Homogenize the cells using a QIAshredder column (Qiagen) and process total RNA according to the manufacturer's instructions.
4. Elute the total RNA with DEPC-treated water.
5. Quantify by determining the optical density at 260 nm and 280 nm. The 260:280 ratio should be at least 1.7.
6. Store at −20°C.
7. Prepare cDNA from the total RNA by reverse transcriptase (RT) PCR using the Advantage RT-for-PCR kit according to the manufacturer's instructions.
8. Perform a PCR reaction with the cDNA from the transfected cells and forward and reverse primers corresponding to the Gα insert and the vector, respectively.
Note: If the insert is present, the primers for the Gα minigenes amplify a 434-bp fragment. No band is observed in cells transfected with the empty pcDNA3.1(-) vector (24).
Verifying Infection with the Retrovirus by GFP Expression
To determine the expression of the retroviral vector construct, we tested the efficiency of infection of pRevTRE2-dEGFP in primary cerebellar nodulus prepared from postnatal day 8 C57BL/6 mice.
1. Overdose the mice with an intraperitoneal administration of 60 mg/kg of sodium pentobarbital.
2. Perfuse the mice through the ascending aorta with PBS (Recipe 6).
3. Open the cranium and remove the brain.
4. Separate the cerebellum from the underlying pons and strip the meninges.
5. Cut in the sagittal plane with a McIlwain tissue chopper set at 300 µm.
6. Transfer the slices through the cerebellar vermis to cold Gey's balanced salt solution with 5 mg/ml glucose.
7. Carefully sever the folium X (also known as the nodulus), the adjacent white matter, and the ventral uvula.
8. Place the explants on the membrane of a Millicell-CM culture plate insert in 1°Culture Medium (Recipe 7) and incubate at 37°C in a humidified atmosphere with 5% CO 2 for 2 hours.
9. Infect the explants with the retrovirus construct (titer 1 × 10 5 pfu per ml; use 500 µl per well of a 6-well plate) and grow at 37°C in a humidified atmosphere with 5% CO 2 (27) for 48 hours.
10. Induce GFP expression with fresh 1°Culture Medium (Recipe 7) containing 2 µg/ml per well of doxycycline for 24 to 48 hours.
11. Visualize the presence of GFP using a fluorescent microscope (Fig. 3 ). 
P R O T O C O L
Determining Minigene Peptide Expression by Ion Mass Spray Analysis
Because the minigene approach depends on competitive inhibition, a key element for success is the expression of amounts of peptides adequate to block intracellular signaling pathways. To verify that the peptides are being produced in the transfected cells, the cytosolic extracts can be analyzed by HPLC, and the resulting peaks analyzed by ion mass spray analysis (20) . This type of analysis can be performed on any of the transfected cells (HEK or HME cells) described above.
1. Trypsinize the cells with 1 ml of Detachment Buffer (Recipe 8) 48 hours after transient transfection.
2. Collect the aspirate and pellet the cells by centrifugation at 750g for 10 min.
3. Wash the cell pellet twice with 1 ml of PBS (Recipe 6).
Note: Pelleted cells can be immediately processed or stored at −80°C.
4. Homogenize the pelleted cells for 15 s with an ESGE Bio-homogenizer M133/1281-0 in 1 ml of Fractionation Buffer (Recipe 9).
5. Centrifuge the homogenate at 3000g for 20 min at 4°C. Save the supernatant and pellet.
6. Centrifuge the supernatant from the previous spin (Step 5) at 100,000g for 30 min at 4°C.
7. Collect the supernatant (cytosolic fraction) and store at −80°C until needed.
8. Load 100 µl of the cytosolic fraction onto a C4 column equilibrated with HPLC Buffer A (Recipe 10).
9. Elute the peptide using a gradient of HPLC Buffer B (Recipe 11). Increase the percentage of HPLC Buffer B from 0 to 60% over 45 min.
10. Collect the peaks.
11. Lyophilize.
12. Send samples for ion mass spray analysis.
Note: As a rule, the peaks generated from the minigene peptides come off between 12 and 14 min.
Determining Minigene Peptide Expression by M 2 AChR Activation Assay
The expression of the minigene constructs can be analyzed by testing their cellular effects on M 2 AChR-mediated activation of I KACh currents. The cellular system used to test whether minigene constructs encoding the Gα subunits' 11 COOH-terminal amino acid residues effectively inhibit GPCR-mediated cellular responses should be well established for (i) the importance of the Gα COOH terminus and (ii) the output of the downstream effector system. Many studies have shown that the M 2 AChR couples exclusively to the G i and G o families of G proteins (28) (29) (30) (31) . The M 2 AChR can efficiently couple to mutant G q in which the last five amino acids of G q are substituted with the corresponding residues from G i or G o , (32) , suggesting that this receptor contains domains that are specifically recognized by the COOH-terminus of G i and G o subunits. A well-characterized downstream effect of M 2 AChR activation is the stimulation of I KACh . In cardiac cells, the I KACh channel is formed as a heterotetramer of GIRK, with two GIRK1 and two GIRK4 subunits (33, 34) . This channel is activated upon stimulation of M 2 AChR in a manner that is completely pertussis toxin-sensitive and is the prototype for a direct Gβγ-activated channel (35) (36) (37) . GIRK channels modulate electrical activity in many excitable cells [see reviews (38) (39) (40) ]. Because the channel opens as a consequence of a direct interaction with Gβγ, whole-cell patch clamp recording of I KACh can be used as a readout of G protein activity in single intact cells. (Fig. 4) . To minimize variations due to differences in transfections or culture conditions, control experiments (transfection with pcDNA or pcDNA-G i R) should be done in parallel with the minigene transfections.
1. Transfect the HEK cells as described in Cell Culture and Transfection: Human embryonic kidney (HEK) 293 cells.
2. After 24 hours, re-plate the transiently transfected cells at a low density onto glass coverslips in complete DMEM medium (Recipe 1).
3. Submerge coverslips in a recording chamber in Extracellular Patch Clamp Solution (Recipe 13) at room temperature.
4. Prepare patch-pipettes from borosilicate glass capillaries using a horizontal pipette puller. 7. Analog filter the signals using a lowpass Bessel filter (1 to 3 kHz corner frequency).
8. Store the data digitally in an IBM-compatible personal computer equipped with a hardware and software package (ISO2) for voltage control, data acquisition, and data evaluation.
9. Set the potassium equilibrium potential to −50 mV and the holding potential to −90 mV (40, 41) to measure K + currents in the inward direction.
10. Apply 1 µM ACh using a solenoid-operated superfusion device, which allows for solution exchange within 300 msec, to produce agonist-induced currents.
11. Apply linear voltage ramps (from −120 mV to +60 mV within 500 ms) every 10 s.
12. Resolve the current voltage properties of the agonist-induced currents by subtracting non-agonist-dependent currents.
13. Measure the maximal current density (peak amplitude) of ACh-induced I KACh currents −80 mV and compare in the presence of the various minigenes. 
Determining Minigene Peptide Expression by PAR1 Activation of Ca 2+ Channels
Another cellular system that can be used to test the effects of minigene vectors is the thrombin receptor (PAR1)-mediated activation of Ca 2+ channels. Thrombin stimulation initiates a calcium response in endothelial cells, and the PAR1 couples to members of the G i , G q , and G 12 subfamilies. To determine which of the COOH-terminal minigenes could affect intracellular calcium concentration ([Ca 2+ ] i ), single cell fluorescence measurements of intracellular calcium (Fig. 5 ) can be determined in HME cells transfected with minigene DNA from the members of the three relevant subfamilies [see Cell Culture and Transfection: Human microvascular endothelial (HME) cells]. To minimize variations due to differences in transfections or culture conditions, control experiments (transfection with pcDNA or pcDNA-G i R) should be done in parallel with the minigene transfections.
This protocol describes how to detect calcium transients by exposing the cells to calcium-sensitive dyes and then measuring the difference in calcium-induced fluorescence before and after stimulation. The data are collected with an upright Olympus microscope (BX 50WI) equipped with Hamamatsu digital video camera linked to a computer using MetaMorph 3.5 software. Images are quantified using the NIH Image Program. 1. Transfect the HME cells as described above in Cell Culture and Transfection: Human microvascular endothelial (HME) cells].
2. Allow the cells to grow for 48 hours in an atmosphere of 95% air and 5% CO 2 at 37°C.
3. Transfer the cells at a low confluency to coverslips in a 24-well plate and allow to adhere for 2 to 4 hours.
Note: Low confluency is needed to minimize errors caused by gap junctions between the cells and to avoid excessive background fluorescence.
4. Aspirate the medium and add 0.5 ml of Calcium Loading Buffer (Recipe 14) to each coverslip.
5. Incubate at 37°C for 30 min.
6. Wash the cells twice with 1 ml of Ca 2+ Buffer (Recipe 15).
7. Place the coverslips in a chamber mounted on the stage of an upright microscope.
Note: Once the cells are mounted on the microscope, the experiment proceeds at room temperature.
8. Establish basal conditions for 40 s with recordings (1000 ms exposure time) every 10 s with an upright Olympus microscope (BX 50WI) equipped with Hamamatsu digital video camera linked to a computer using MetaMorph 3.5 software.
9. Add 70 nM thrombin to stimulate the cells.
10. Record calcium fluorescence (1000 ms exposure time) every 10 s for 170 s after stimulation with thrombin.
11. Quantify the images using NIH Image software. 
P R O T O C O L
Testing Cellular Effects of Retroviral Minigene Vectors Using Transendothelial Electrical Resistance
The retroviral minigene vector provides uniform expression efficiency, such that nearly 100% of the cells are infected (Fig. 3) . Thrombin induces increased vascular permeability in endothelial cells that can be seen as a 40 to 50% decrease in transendothelial electrical resistance [(43, 44) (Fig. 6) ]. Endothelial cell retraction in response to thrombin measured in real time, following infection of the retroviral minigene vectors into HME cells and induction of expression with doxycycline, can be used to determine the effectiveness of the minigene constructs in inhibiting G protein signaling. To minimize variations due to differences in infections or culture conditions, control experiments (pRevTRE2-G i R) should be done in parallel with the retroviral minigene infections.
1. Infect HME cells with minigene retrovirus (1 × 10 5 pfu/ml; use 500 µl per well for 6 well plate), as described above (see Cell Culture and Transfection: Viral infection of cells).
2. Grow the infected cells for 24 hours in Complete MCDB 131 (Recipe 4) in an atmosphere of 95% air and 5% CO 2 at 37°C.
3. Plate cells onto gelatin-coated gold electrodes (4.9 × 10 4 cm 2 ) and induce with 2 µg per ml doxycycline to begin expression of the COOH-terminal peptides. 
Troubleshooting
The only limitation we have found with the minigene vectors is the level to which they can be expressed relative to the level of receptor in question. Because the expressed peptides are competitive blockers, it is critical that they accumulate to an effective concentration. Thus, a potential problem occurs if both the receptor and minigene vector are transiently transfected into the cells. Better results are obtained with a receptor that is endogenous to the cell line, and only the minigene vector is transiently transfected. Alternatively, a cell line can be used that contains stably transfected receptors. We are currently developing cell lines in which the minigene vectors are stably expressed and whose expression can be induced. Minigene vectors can block thrombin-induced endothelial barrier dysfunction. HME cells were infected with retroviral minigenes, plated on gold electrodes, and induced with doxycycline to produce the peptides. After serum deprivation, cells were stimulated with 25 nM thrombin, and changes in transendothelial electrical resistance were monitored in real time. A representative from at least three experiments is shown. Statistical analysis was performed with the peak values. The peak value from G q minigene transfected cells was significantly smaller than the peak value for G i R minigene transfected cells (Paired Student's t-test, P < 0.05).
Notes and Remarks
The minigene approach has been used to examine various responses related to G proteins, including (i) binding of pleckstrin homology (PH) domains to Gβγ (45), (ii) inhibiting GPCRs by expression of the COOH terminus of β 2 adrenergic receptor kinase (46) (47) (48) , and (iii) identifying intracellular domains of GPCRs critical for G protein coupling (45, 49, 50) . Minigenes expressing the last 55 amino acids of G q were used to target the receptor-G q interface to achieve G protein class-specific inhibition (51) . Transient transfection of COS-7 cells with α 1B -adrenergic receptors or M 1 muscarinic receptors and the G q COOH-terminal minigene (residues 305 to 359) inhibits agonist-stimulated inositol phosphate (IP) production, whereas coexpression with the G q NH 2 terminus (residues 1 to 54) has no effect.
The molecular interactions that occur between receptors and G proteins are fundamental to the transduction of environmental signals into specific cellular responses. The extreme COOH-terminus of Gα has been established as an important mediator of the GPCR-G protein interaction. We have developed a novel strategy to block receptor-G protein coupling by using minigene plasmid vectors that express Gα COOH-terminal peptides after their transfection or infection into mammalian cells. The approach has given us a wealth of information about which G proteins are activated through which receptors. In addition, we have begun to use the minigenes to tease out the actual contact sites of G proteins at the GPCR interface. Our experiments indicate that GPCRs coupled to multiple G proteins use different cytoplasmic sites to interact with different G proteins. Thus, it appears that the minigene vectors and the inducible retroviral vectors will prove to be important research tools for dissecting out the roles and interactions that occur between GPCRs and their cognate G proteins.
